In the last decade, the use of cancer immunotherapy with immune checkpoint inhibitors (ICIs) as monotherapy was defined by durable responses in numerous indications and paved the way for novel therapeutic strategies to improve treatment outcomes. Allucent identified the clinical development trends in this field that clearly favour ICIs being assessed primarily as part of combination therapies.
Interested in how this clinical trial landscape shifted between 2019 and the 1st half of 2020? Read the full article of our clinical experts below.
White paper highlights:
- Immune checkpoint inhibitor (ICI) monotherapy holds the promise for durable responses in adequately selected patient subsets and opens the door for novel therapeutic strategies to improve current treatment outcomes
- Allucent’s analysis of ongoing Phase II and III trials between 2019 and the 1st half of 2020 identified clinical development trends that clearly favor ICIs being assessed primarily as part of combination therapies, with the Top 5 combinations being ICIs plus either targeted therapy, chemotherapy, another ICI, radiotherapy or chemoradiotherapy
- ICI combination therapies remain predominantly evaluated in solid tumors, with the most commonly investigated indications being lung, head and neck, esophageal, melanoma, renal, breast, bladder and gastric cancers
- Next-generation ICIs that target different immune pathways are entering the clinic beyond proof-of-concept trials and several combinations with these next-generation ICIs are currently in clinical development